Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib Plus Copanlisib in RAIR Thyroid Cancer
NCT04462471Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vemurafenib and copanlisib in thyroid cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Dose-limiting Toxicity at 6 months. Started Jun 2020; status: completed.
02
Drugs
vemurafenibcopanlisib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT04462471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04462471.